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Context: Birth triggers a large fetal neuroendocrine response, which is more
pronounced in infants born vaginally than in those born by elective cesarean section
(ECS). The two related peptides arginine vasopressin (AVP) and oxytocin (OT) play an
essential role in peripheral and central stress adaptation and have a shared receptor
mediating their function. Elevated cord blood levels of AVP and its surrogate marker
copeptin, the C-terminal part of AVP prohormone, have been found after vaginal delivery
(VD) as compared to ECS, while release of OT in response to birth is controversial.
Moreover, AVP, copeptin and OT have not yet been measured simultaneously at birth.
Objective: To test the hypothesis that AVP but not OT levels are increased in infants
arterial umbilical cord blood in response to birth stress and to characterize AVP secretion
in direct comparison with plasma copeptin.
Methods: In a prospective single-center cross-sectional study, we recruited healthy
women with a singleton pregnancy and more than 36 completed weeks of gestation
delivering via VD or ECS (cesarean without prior uterine contractions or rupture of
membranes). Arterial umbilical cord blood samples were collected directly after birth,
centrifuged immediately and plasma samples were frozen. Concentrations of AVP
and OT were determined by radioimmunoassay and that of copeptin by ultrasensitive
immunofluorescence assay.
Results: A total of 53 arterial umbilical cord blood samples were collected, n = 29 from
VD and n = 24 from ECS. Ten venous blood samples from pregnant women without
stress were collected as controls. AVP and copeptin concentrations were significantly
higher in the VD group than in the ECS group (both p < 0.001), median (range)
AVP 4.78 (2.38–8.66) vs. 2.38 (1.79–3.88) (pmol/L), copeptin 1692 (72.1–4094) vs.
5.78 (3.14–17.97), respectively, (pmol/L). In contrast, there was no difference in OT
concentrations (pmol/L) between VD and ECS, 6.00 (2.71–7.69) vs. 6.14 (4.26–9.93),
respectively. AVP and copeptin concentrations were closely related (Rs = 0.700,
p < 0.001) while OT did not show any correlation to either AVP or copeptin. In linear
regression models, vaginal delivery and biochemical stress indicators, base deficit and
pH, were independent predictors for both AVP and copeptin. OT was not linked to base
deficit or pH.
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Conclusion: Vaginal birth causes a profound secretion of AVP and copeptin in
infants. Whereas AVP indicates acute stress events, copeptin provides information
on cumulative stress events over a longer period. In contrast, fetal OT is unaffected
by birth stress. Thus, AVP signaling but not OT mediates birth stress response
in infants. This unique hormonal activation in early life may impact neurobehavioral
development in whole life.
Keywords: antidiuretic hormone, copeptin, oxytocin, parturition, children, stress, brain
INTRODUCTION
Childbirth involves a complex hormonal action including
the peptides arginine vasopressin (AVP) and oxytocin (OT)
to facilitate fetal adaptation from intra- to extra-uterine
life, involving cardiovascular and pulmonary adaptation,
thermoregulation, metabolic homeostasis and behavior
(Schorscher-Petcu et al., 2010; Wellmann and Bührer, 2012;
Evers and Wellmann, 2016; Kasser et al., 2019).
AVP, also known as antidiuretic hormone, is produced as a
larger precursor AVP prohormone in the hypothalamus, cleaved
in different peptides, including the bioactive non-apeptide AVP
and copeptin, the C-terminal part of AVP prohormone. These
are eventually secreted in equimolar amounts by the posterior
pituitary gland (Christ-Crain, 2019). The physiological functions
of AVP, i.e., homeostasis of fluid balance, vascular tone and
regulation of the endocrine stress response, are mediated by three
AVP receptors, V1aR, V1bR, and V2R that are encoded for by
three separate genes (Carter et al., 2020).
Similar to AVP, OT is also synthesized in the hypothalamus
and differs in only two amino acids from its evolutionary older
sister peptide AVP and exerts its action via the OT receptor
(OTR), including patterns of growth, resilience, and healing
with stress-coping, anti-inflammatory, and antioxidant functions
(Robert and Clauser, 2005). However, AVP and OT bind with
similar affinity to their cognate receptors OTR and V1aR.
At the end of pregnancy, the maternal level of oxytocin rises,
and a noticeable surge of maternal OT occurs at parturition in
the mothers blood (Ross and Young, 2009; Uvnäs-Moberg et al.,
2019). However, data on human fetal OT levels are conflicting
with studies reporting an increase in response to birth stress
(Marchini et al., 1988; Lindow et al., 1998) while others did not
(Patient et al., 1999). An array of conditions that stimulate release
of AVP, such as low blood pressure, high osmolarity, hypoxia,
pain, and stress, also regulate oxytocin secretion.
On top of their broad peripheral actions, both peptides
AVP and OT are well known for their distinct neurobehavioral
actions (Neumann and Landgraf, 2012; Carter et al., 2020).
Interestingly, due to a large structural homology between the
OT receptor and the main AVP receptor (V1aR), there is
significant cross-reactivity between the ligands and receptors
resulting in overlaps of AVP and OT peripheral and central
actions (Pierce et al., 2020).
In contrast to OT, which ideally is determined in blood
by OT itself, AVP concentrations in blood can be deduced
from analyzing copeptin concentrations. In fact, copeptin
measurement achieved wide clinical utility as copeptin is much
more stable than AVP and can be determined quantitatively in
an automated fashion (Morgenthaler et al., 2006; Fenske et al.,
2018). Despite its use as a diagnostic marker in a large variety
of diseases, the physiological function of copeptin is widely
unknown (Christ-Crain, 2019).
AVP, its surrogate marker copeptin and OT were measured
each in many studies on fetal response to childbirth (Wellmann
et al., 2010; Evers and Wellmann, 2016). There is large agreement
that birth stress causes fetal AVP and copeptin secretion in
humans and other species, e.g., rodents (Evers and Wellmann,
2016; Summanen et al., 2018). However, there is no study yet
published showing AVP and copeptin measurements in parallel
in infants which is unlike adults (Christ-Crain, 2019).
The present study was designed to directly compare for the
first time the three peptides, AVP, copeptin, and oxytocin, in
arterial umbilical cord blood samples in response to birth stress.
The two aims of our study were first, to assess whether fetal
OT level respond to birth stress by comparing fetal arterial
umbilical cord blood OT levels after vaginal delivery (VD) and
elective cesarean section (ECS) and, second, to assess AVP and
copeptin in parallel.
MATERIALS AND METHODS
This prospective, cross-sectional study was conducted in a
University women’s and children’s hospital in Germany. The
study was approved by the Ethics Committee of the University
of Regensburg (file number: 20-1876-101) and written consent
was obtained prior to enrollment. Inclusion criteria for both
birth modes, VD and ECS, were singleton pregnancy and a
gestational age of 37-42 weeks. ECS was defined as cesarean
section done either on maternal request or due to medical
indications, such as breech presentation or repeated cesarean.
Hence, no onset of labor, meaning no uterine contractions
or rupture of membranes before ECS, was mandatory. In
contrast, instrumental VD and secondary cesarean (defined as
cesarean section after the onset of uterine contractions, e.g.,
due to pathological fetal heart rate tracing) was an exclusion
criterion. Further maternal exclusion criteria were infections,
hypertension, preeclampsia, and substance abuse. Fetal exclusion
criteria were fetal malformation, chromosomal aberration, fetal
growth restriction and infections. Infants requiring advanced
medical support and admitted to the neonatal intensive care unit
were also excluded from the study.
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In addition, venous blood samples from 10 healthy pregnant
women (37-40 weeks of gestation) at regular pregnancy control
visits and before the onset of uterine contractions or rupture of
membranes, were used as controls. The inclusion and exclusion
criteria for this group were the same as above.
Arterial umbilical blood samples (0.5 mL) were collected
directly after birth into EDTA tubes and plasma was frozen at
−20◦C (maximum within 30 min after delivery). All samples
were centrifuged by 4◦C up to 10 min with a relative centrifugal
force of 1,300 g according to a previously published protocol
(Kagerbauer et al., 2013). AVP and OT were measured by using
highly sensitive and specific radioimmunoassays (RIAgnosis,
Regensburg, Germany). In detail, plasma samples were stored
at −20◦C until extraction using LiChroprep Si60 heat-activated
at 700◦C for 3 h. 20 mg of LiChroprep Si60 in 1 mL of
distilled water was added to each sample, which was then
mixed for 30 min, washed twice with distilled water and 0.01
N HCI and eluded with 60% acetone. The extraction recovery
range was 85–90%. The data was not corrected for recovery.
After evaporation, 50 µL of an assay buffer was added to
the extract to assay OT and AVP using specific and sensitive
radioimmunoassays. Briefly, 50 µL of an antibody was added
to each sample. Following a 1-h preincubation period, 10 µL
of 125I-labeled tracer was added to the sample, which was
then incubated for 3 days at 4◦C. Unbound radioactivity was
precipitated by activated charcoal. In these environments, on
average 50% of total counts are bound with < 5% non-specific
binding. The detection limit is in the 0.1–0.5 pg/sample range,
depending on the age of the tracer, with typical displacements
of 20–25% at 2 pg, 60–70% at 8 pg, and 90% at 32 pg of
standard neuropeptide.
Measurements of copeptin were done by using an
ultrasensitive immunofluorescence assay (Evers and Wellmann,
2016). The laboratory staff was blinded to the aims of the study.
Information concerning maternal body mass index prior
to pregnancy, gestational age at delivery, delivery parameters
(umbilical blood pH and base excess-BE) and newborn
characteristics at birth (weight, head circumference, length,
Apgar levels) were collected.
Continuous variables (median with IQR) were compared with
the Mann-Whitney U-test and categorical variables (number
of cases, %) with the chi-square test. Spearman’s rank-order
correlation was applied to assess the correlation among AVP,
copeptin, and OT. Univariable linear regression analysis was
used to explore the effect of delivery mode, sex, gestational age,
birth weight, umbilical blood pH and base deficit (independent
variables) on the log-transformed AVP, copeptin, and OT
levels (dependent variables). Parameters with P < 0.1 in the
univariable analysis were included in multivariable models.
Statistical analyses were performed using the IBM SPSS version
25 (IBM Corp., Armonk, NY).
RESULTS
In total, 29 subjects were included in the VD group and
24 in the ECS group. There were no differences in mothers
somatometric data and infants weight, head circumference, sex
and postnatal adaptation characteristics between the two groups
(Table 1). In contrast, delivery was on average 10 days earlier,
infants length slightly smaller, and the arterial umbilical cord
blood less acidotic (higher pH and/or less BE) in the ECS
group (Table 1).
AVP and copeptin levels were higher in the VD group
(AVP median 4.78 pmol/L, IQR 2.93–6.16; copeptin median
1,691 pmol/L, IQR 704–2,568 pmol/L) as compared to the ECS
group (AVP median 2.38 pmol/L, IQR 1.9–2.91 pmol/L; copeptin
median 5.78 pmol/L, IQR 4.75–7.16 pmol/L; p < 0.001 for both
comparisons). In contrast, OT levels were similar between the
two (VD: 6.0 pmol/L, IQR 5.61–6.56 pmol/L; ECS: 6.14 pmol/L,
5.38–7.96 pmol/L) (Figure 1).
There was a strong correlation between AVP and copeptin
(Spearman’s rho 0.700, p < 0.001) but not between AVP and
OT (–0.031, p = 0.825) or between copeptin and OT (–0.185,
p = 0.185). AVP and copeptin were negatively correlated with
the pH (–0.603 and –0.738, respectively) and the BE (–0.597
and –0.749, respectively) (p < 0.001 for all correlations). There
was no correlation between OT and pH or between OT and BE
(data not shown).
Linear regression analyses showed that VD and umbilical cord
blood acidity were both independent predictors of AVP and
copeptin levels, while the OT levels were unrelated to any of the
clinical or biochemical parameters (Table 2).
When comparing AVP, copeptin and OT concentrations
in all infants (n = 53) with those of the pregnant women
before the onset of labor (control group, n = 10), all three
peptides were significantly higher in infants. More specifically,
AVP was 2.93 pmol/L (median; IQR 2.38–4.92 pmol/L) in
infants vs. 2.001 pmol/L (1.74–2.77 pmol/L) in controls
(P = 0.042), copeptin 174.4 pmol/L (5.99–1831.5 pmol/L)
vs. 7.44 pmol/L (5.52–9.68 pmol/L) (p < 0.001), and OT
6.06 pmol/L (5.59–7.16 pmol/L) vs. 4.00 pmol/L (3.69–
4.26 pmol/L) (p < 0.001), respectively.
DISCUSSION
The peptides AVP and OT are key hormones in the peripheral
system and in the brain with largely opposite roles in
modulating stress, anxiety, and social behaviors (Neumann and
Landgraf, 2012). However, due to high sequence homology
between both peptides and their receptors, there are many
signaling interactions (Jurek and Neumann, 2018) but the
conditions of their crosstalk remain in general unclear (Rae
et al., 2021) and particularly in the process of childbirth
(Wellmann and Bührer, 2012).
To clarify the effect of birth stress on the secretion of these
peptides, the present study aimed to assess for the first time
simultaneously the levels of AVP, OT, and the AVP surrogate
marker copeptin in fetal arterial umbilical cord blood at birth.
The main finding was that in contrast to OT, both AVP and
copeptin are significantly increased after VD as compared to
deliveries without preceding birth stress, namely ECS. Thus, OT
secretion in infants is not subject to birth stress.
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TABLE 1 | Characteristics of mothers and newborns, and pregnancy outcome according to mode of delivery.
Vaginal delivery (n = 29) Elective cesarean section (n = 24) P
Age of gestation (days) 281 (273–285) 271 (267–274) <0.001
Mother body mass index 22.7 (20.8–24.7) 22.7 (21.1–23.9) n.s.
Infant weight (g) 3,535 (3,238–3,668) 3,310 (2,970–3,548) n.s.
Infant length (cm) 53 (51–55) 51 (50–53) 0.029
Infant head circumference (cm) 35 (34–37) 35 (34–36) n.s.
Infant sex, male 17 (59) 14 (58) n.s.
pH arterial umbilical cord blood 7.21 (7.19–7.32) 7.33 (7.31–7.36) <0.001
BE arterial umbilical cord blood −5.7 (−7.35 to −4.30) −1.60 (−2.20 to −1.00) <0.001
Apgar 5 min > 5 24 (79) 21 (88) n.s.
Apgar 10 min > 5 29 (100) 23 (96) n.s.
Data are median (IQR) or number of cases (%). Body mass index prior to pregnancy. Comparisons were performed with Mann-Whitney U or chi-square test, as appropriate.
n.s., not significant; BE, base excess.
FIGURE 1 | Arginine Vasopressin (AVP), copeptin and oxytocin (OT) levels according to mode of delivery. Comparisons were performed with Mann-Whitney U-test.
VD, vaginal delivery; ECS, elective cesarean section.
Determination of AVP and OT levels in clinical settings
is challenging, as half time of both peptides is short and
in particular their stability in sampling matrices is very low
(Morgenthaler et al., 2006; Muttenthaler et al., 2010). In contrast
to AVP, for which a more stable surrogate marker has been
identified and developed for clinical routine, namely copeptin,
there is no such alternative for OT. Thus, we set up a strict
sampling protocol to achieve fast and reliable processing in
all analytes for this study. The results indicate twofold higher
AVP values in VD as compared to ECS and almost 300-fold
higher copeptin values in VD as compared to ECS. These
magnitudes for AVP and copeptin are in line with previous
reports as summarized by Evers and Wellmann (2016). However,
we are the first presenting AVP and copeptin data from same
samples at birth. There was an average twofold increase of
AVP associated with birth while copeptin increased more than
200-fold. As AVP has a very short half-life compared with
copeptin and both are released at equimolar amounts, we
assume that AVP is repetitively released with each uterine
contraction but degraded in the blood soon thereafter, while
copeptin accumulates.
Since we strictly followed previously published protocols on
sampling and post-sampling handling with immediate cooling
down to preserve stability of all peptides (Kagerbauer et al.,
2013), we conclude that the observed huge difference noted
between AVP and copeptin concentrations in umbilical cord
blood when comparing VD and ECS is most likely caused due
to a difference in half-life of AVP and copeptin once secreted
into the circulatory system. Based on our results, the half-
life differs by a factor up to 100. Assuming for AVP a half-
life of few minutes in the circulatory system (Morgenthaler
et al., 2006), that of copeptin is in the range of hours. This
fits very well to the different stress levels fetuses experience
during VD and ECS (Evers and Wellmann, 2016). Therefore
we propose the following concept: The fetus secretes AVP
and copeptin from the pituitary gland in a 1:1 ratio into the
circulatory system upon relevant uterine contractions. Whereas
AVP is cleared within minutes, copeptin accumulates over time.
Thus, AVP level reflects short-range stress and that of copeptin
represents the sum of all stress events summoned over a long
period of many hours.
In the present analysis, oxytocin levels were completely
unaffected by the mode of delivery and did not show any
association to clinical and biochemical stress indicators nor to
AVP or copeptin. This confirms previous findings by Patient
et al. (1999) and supports the notion that AVP but not
OT is subject to fetal birth stress (Wellmann and Bührer,
2012). Thus, in respect to fetal stress we conclude that AVP
is the driver in mediating peripheral and central response
supporting infants transition from intra-uterine to extra-uterine
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TABLE 2 | Effect of various parameters on arterial umbilical cord blood levels of
arginine vasopressin, copeptin, and oxytocin.
Unadjusted effect Adjusted effect
Beta coefficient b P Beta coefficient p
AVP
Vaginal delivery 0.667 <0.001 0.336 0.030
Male sex 0.151 0.280 − −
GA 0.468 <0.001 0.134 0.308
BW 0.307 0.025 0.034 0.771
Umbilical blood pH −0.620 <0.001 −* −
Umbilical blood BE −0.644 <0.001 − 0.372 0.010
Copeptin
Vaginal delivery 0.953 <0.001 0.758 <0.001
Male sex 0.086 0.542 − −
GA 0.544 < 0.001 0.049 0.264
BW 0.237 0.088 –0.048 0.228
Umbilical blood pH −0.720 <0.001 −*
Umbilical blood BE −0.763 <0.001 –0.276 <0.001
OT
Vaginal delivery −0.242 0.081 −0.162 0.327
Male sex −0.035 0.803 − −
GA −0.235 0.090 −0.145 0.378
BW −0.064 0.651 − −
Umbilical blood pH 0.197 0.167 − −
Umbilical blood BE 0.122 0.400 − −
Linear regression analyses, using log-transformed AVP, copeptin or OT values as
dependent variable. The unadjusted effect refers to the influence of each parameter
separately (univariable analyses). The adjusted effect refers to the influence of each
parameter after correcting for the effect of the others (multivariable analysis). Only
parameters with P < 0.1 in the univariable models were included in the multivariable
analysis.
*Not included in the final model due to significant collinearity with pH.
Coefficients of determination (R2) for the multivariable models: AVP 0.529, copeptin
0.946, OT 0.073.
AVP, arginine vasopressin; OT, oxytocin; GA, gestational age; BW, birth weight, BE,
base excess.
life (Evers and Wellmann, 2016; Spoljaric et al., 2017). Regarding
the maternal part, OT is a key hormone in childbirth, and
synthetic oxytocin is widely administered to induce labor (Uvnäs-
Moberg et al., 2019). In fact, mild uterine contractions are
sufficient to trigger fetal copeptin release (Wellmann et al.,
2016) and a large multicenter randomized controlled trial is
underway to study the clinical effect of mild uterine contractions
prior to ECS on infants and mothers outcome after birth
(Wellmann et al., 2021).
Animal models support the findings of a perinatal surge in
AVP and copeptin with higher levels in plasma after a vaginal
than a Cesarean section (Hoffiz et al., 2021). In parallel to the
increase in the peripheral blood circulation also central AVP
mRNA levels and AVP protein levels rise significantly at birth
(Spoljaric et al., 2017; Hoffiz et al., 2021). Hypoxic events, which
in human fetuses accompany regularly uterine contractions
before birth, have been identified in animal models as large
driver of AVP and copeptin release into the peripheral blood
circulation and in specific brain regions (L’Abate et al., 2013;
Coldren et al., 2017; Summanen et al., 2018). Whereas increased
AVP levels in plasma were found to be associated with decreased
plasma osmolality after a vaginal, but not Cesarean section birth
(Hoffiz et al., 2021), central AVP increase is related to reduced
neuronal cell death in specific brain areas (Hoffiz et al., 2021) and
suppress energetically expensive correlated network events under
conditions of reduced oxygen supply at birth (Spoljaric et al.,
2017). To what extent peripheral or central AVP mechanisms
may contribute to birth related natural analgesia in human
neonates is under discussion (Kasser et al., 2019).
Strengths of our study include the prospective design, the strict
adherence to sampling and post-sampling protocols as well as
state of the art measurement of peptides. Limitations include the
lack of maternal blood samples in parallel to that from fetuses and
the lack of additional measurements within the first hours of life
to determine the half-life of AVP and copeptin in the peripheral
circulation of neonates.
In conclusion, AVP and copeptin reflect both birth stress but
whereas AVP indicates acute stress events, copeptin provides
information on cumulative stress events over a longer period. In
contrast to AVP and copeptin, OT level in infants at birth are not
associated with any clinical or biochemical stress indicator, thus,
OT is not subject to fetal stress response during birth.
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